DexCom, Inc. (NASDAQ:DXCM) Shares Sold by First Turn Management LLC

First Turn Management LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 17.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 160,096 shares of the medical device company’s stock after selling 32,836 shares during the period. DexCom makes up approximately 3.0% of First Turn Management LLC’s investment portfolio, making the stock its 17th biggest holding. First Turn Management LLC’s holdings in DexCom were worth $18,152,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of New Hampshire acquired a new position in DexCom during the first quarter valued at $1,508,000. Eagle Asset Management Inc. lifted its position in DexCom by 21.5% during the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock valued at $217,929,000 after purchasing an additional 310,728 shares during the period. Alberta Investment Management Corp lifted its position in DexCom by 27.0% during the fourth quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock valued at $40,123,000 after purchasing an additional 68,723 shares during the period. Artisan Partners Limited Partnership lifted its position in DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the period. Finally, Los Angeles Capital Management LLC lifted its position in DexCom by 62.5% during the first quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock valued at $49,520,000 after purchasing an additional 137,336 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ:DXCM opened at $68.82 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The firm has a market capitalization of $27.37 billion, a price-to-earnings ratio of 44.40, a PEG ratio of 2.12 and a beta of 1.18. The company’s 50-day moving average is $83.24 and its two-hundred day moving average is $111.61. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 EPS. Analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The disclosure for this sale can be found here. Insiders have sold 2,483 shares of company stock worth $201,708 in the last ninety days. 0.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on DXCM shares. Oppenheimer decreased their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. Royal Bank of Canada cut their price objective on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a report on Friday, July 26th. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $145.00 to $75.00 in a report on Friday, July 26th. Finally, Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.